The company’s management expressed confidence in the successful completion of the work.
Moderna Inc said on Sunday that it received an additional $ 472 million from the office of higher biomedical research to develop a vaccine for the new coronavirus.
The US-based drug company explained that the additional funding is intended to help the company’s work in late-stage clinical trials.
In April, Moderna received 483 million from the Federal Agency that finances the development of medical technologies. This happened at a time when the event of an experimental vaccine was at an early stage – at the scene of trials conducted by the National Institutes of health.